Idelalisib

Idelalisib is an oral targeted anticancer medicine belonging to the phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor class. It blocks the PI3K delta enzyme, which helps regulate the survival, growth, and movement of B lymphocytes, a type of white blood cell. In certain blood cancers, this signaling pathway supports the survival of abnormal B cells. By inhibiting PI3K delta, idelalisib interferes with these signals and can reduce the activity and survival of malignant cells. The medicine is taken by mouth as a tablet and has been used in selected adults with chronic lymphocytic leukemia (CLL) and certain forms of non-Hodgkin lymphoma, depending on the applicable regulatory approval. For CLL, it has been administered in combination with an anti-CD20 antibody such as rituximab. Idelalisib is associated with important safety risks, including serious infections, liver inflammation, severe diarrhea or colitis, and inflammation of the lungs. These complications can require treatment interruption or permanent discontinuation. Appropriate patient selection, preventive measures against certain infections, regular laboratory testing, and prompt assessment of new symptoms are essential during therapy. Treatment decisions should account for the cancer type, previous therapies, alternative treatment options, and the patient's overall health.

Idelalisib was developed as a selective inhibitor of the PI3K delta signaling pathway, which is important for the survival and function of B lymphocytes. The United States Food and Drug Administration (FDA) initially approved idelalisib in July 2014 for selected adults with relapsed chronic lymphocytic leukemia in combination with rituximab, as well as for certain patients with follicular lymphoma and small lymphocytic lymphoma under accelerated approval. The European Commission granted marketing authorization for Zydelig, containing idelalisib, on 18 September 2014. Clinical development included the phase III study of idelalisib plus rituximab in previously treated chronic lymphocytic leukemia and studies evaluating its activity in indolent non-Hodgkin lymphoma. Subsequent safety reviews identified serious and potentially fatal infections, liver toxicity, severe diarrhea or colitis, and lung inflammation, leading to additional monitoring requirements and prescribing restrictions. Historical approvals should not be interpreted as confirmation that every indication remains authorized or routinely recommended today. The current regulatory status, available indications, and prescribing requirements should be verified for the relevant country before treatment.

Idelalisib has been used in selected adults with chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma, subject to jurisdiction-specific approvals and subsequent regulatory changes. In chronic lymphocytic leukemia, its established European indication includes use with an anti-CD20 antibody, such as rituximab, in eligible adults who have received previous treatment or who have specific high-risk genetic abnormalities and cannot receive other therapies. In the European Union, idelalisib monotherapy has also been authorized for selected adults with follicular lymphoma that has not responded to two previous lines of treatment. Historical indications in other jurisdictions may differ, and some indications have been withdrawn or restricted. Idelalisib is not appropriate for every patient with these cancers, particularly when safer or more suitable alternatives are available. A hematologist or oncology specialist should assess the current local authorization, previous treatment history, disease characteristics, infection risk, and individual benefit-risk profile before considering therapy.

Idelalisib is administered orally as a tablet and can generally be taken with or without food. The established adult regimen in the product information is 150 mg twice daily, approximately 12 hours apart. If specified toxicities develop, treatment may need to be interrupted and, where permitted by the applicable prescribing information, restarted at a reduced dose of 100 mg twice daily after recovery. Treatment duration depends on the indication, clinical response, tolerability, and current prescribing guidance. Therapy should be reassessed regularly and discontinued when required for severe or recurrent toxicity. Liver function tests, blood counts, and clinical assessment for infection and gastrointestinal or respiratory complications are essential. Preventive treatment against Pneumocystis jirovecii pneumonia is required under relevant prescribing guidance and may need to continue for a period after idelalisib is stopped. The exact regimen, dose modifications, and treatment duration must be determined by the treating specialist using current local product information.

Common side effects of idelalisib include diarrhea, nausea, abdominal discomfort, fatigue, fever, rash, cough, and changes in liver enzyme levels. Reduced neutrophil counts can occur and may increase susceptibility to infection, while increased lymphocyte counts and elevated blood fat levels may also be observed. Diarrhea can range from mild symptoms to persistent inflammation of the intestine, so worsening or prolonged symptoms should not be dismissed as an ordinary side effect. Liver enzyme elevations may occur without noticeable symptoms, making scheduled blood tests important. The frequency and severity of adverse effects vary according to individual health, previous treatments, and other medicines being used. Supportive treatment, closer monitoring, dose interruption, or discontinuation may be necessary. Patients should promptly inform their healthcare team about persistent diarrhea, abdominal pain, fever, yellowing of the skin or eyes, worsening cough, or breathing difficulties.

Idelalisib can cause serious or potentially fatal infections, severe liver injury, diarrhea or colitis, pneumonitis, and intestinal perforation. Important infections include Pneumocystis jirovecii pneumonia and cytomegalovirus infection. Preventive measures and infection monitoring are essential, and treatment should not be initiated in patients with an uncontrolled systemic infection where the applicable prescribing information prohibits use. Liver toxicity can develop early in treatment and may require frequent liver function testing, treatment interruption, dose adjustment, or permanent discontinuation. Severe intestinal inflammation may develop after several months of therapy and can become life-threatening if not recognized promptly. Pneumonitis may present with cough, shortness of breath, or reduced oxygen levels and requires urgent assessment. Severe skin reactions and clinically significant reductions in blood cell counts may also occur. Suspected serious toxicity requires immediate clinical evaluation, and the decision to restart treatment must follow the relevant prescribing guidance and specialist assessment.

Before starting idelalisib, clinicians should review liver function, complete blood counts, infection history, respiratory and gastrointestinal symptoms, and all current medicines. Active infections and factors that increase infection risk should be assessed, with appropriate screening and preventive measures based on clinical circumstances. Liver enzymes and bilirubin require regular monitoring, particularly during the early treatment period. Patients should be evaluated promptly for persistent diarrhea, abdominal pain, fever, cough, or breathing difficulties. Live vaccines should generally be avoided during significant immunosuppression, and vaccination plans should be discussed with the treating clinician. Idelalisib is affected by CYP3A enzymes, so strong CYP3A inhibitors and inducers can alter its exposure and may require avoidance or careful management under the product information. Idelalisib can also inhibit CYP3A and increase exposure to certain other medicines, potentially raising the risk of adverse effects. Prescription medicines, non-prescription products, and supplements should be reviewed by a pharmacist or prescriber. Pregnancy, breastfeeding, and reproductive risks should also be discussed according to current prescribing guidance.

Prescribers should confirm the diagnosis, disease subtype, prior treatment history, and current local indication before initiating idelalisib. Baseline assessments should include liver function, complete blood counts, infection evaluation, and a comprehensive medication review for CYP3A-related interactions. Establish a monitoring schedule for liver enzymes and blood counts, with additional assessment based on symptoms and individual risk factors. Follow the applicable prescribing information for Pneumocystis jirovecii pneumonia prophylaxis and cytomegalovirus monitoring, including management of suspected or confirmed infection. Patients should be counselled to report persistent diarrhea, abdominal pain, jaundice, fever, cough, or breathlessness promptly. Pharmacists should verify the prescribed dose, administration schedule, interaction risks, adherence, and requirements for treatment interruption or dose reduction. Unexplained gastrointestinal or respiratory symptoms should trigger timely clinical assessment rather than routine symptomatic treatment alone. Coordination among hematologists, oncology pharmacists, nurses, and infectious disease specialists, when needed, supports safer treatment and earlier recognition of serious complications.